通化金马：公司研制的化学1类新药琥珀八氢氨吖啶片目前已完成综合审评工作

Group 1 - The company has completed the comprehensive review of its new drug, a chemical Class 1 oral medication for Alzheimer's disease, and is currently in the final review stage [2] - The company has provided all required professional research materials as part of the approval process, and all work is progressing normally [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]